-
-
-
-
-
-
-
FibroGen (FGEN) Says FDA Advisory Committee Voted to Recommend Not Approving Roxadustat
-
-
-
-
-
-
-
FibroGen (FGEN) PT Lowered to $55 at Stifel
-
-
-
-
-
-
-
FibroGen (FGEN) announces FDA will hold an advisory committee meeting to review the new drug application for roxadustat
-
-
-
-
15,404 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

